HCW Biologics Inc.(HCWB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

HCWB HCW Biologics Inc.

Not Yet Opened 12-22 16:00:00 EST

1.56

-0.01

-0.64%

盘后1.56

+0.000.00%

18:57 EST

High1.69	Low1.56	Vol19.54K
Open1.66	D1 Closing1.57	Amplitude8.08%
Mkt Cap4.21M	Tradable Cap2.02M	Total Shares2.70M
T/O31.63K	T/O Rate1.51%	Tradable Shares1.30M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"HCWB","market":"US","secType":"STK","nameCN":"HCW Biologics Inc.","latestPrice":1.56,"timestamp":1766437200000,"preClose":1.57,"halted":0,"volume":19544,"hourTrading":{"tag":"盘后","latestPrice":1.56,"preClose":1.56,"latestTime":"18:57 EST","volume":59,"amount":94.73,"timestamp":1766447873588},"delay":0,"floatShares":1295400,"shares":2701607,"eps":-17.5946,"marketStatus":"Not Yet Opened","change":-0.01,"latestTime":"12-22 16:00:00 EST","open":1.66,"high":1.6869,"low":1.56,"amount":31626.169203999998,"amplitude":0.080828,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-17.5946,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766480400000},"marketStatusCode":0,"adr":0,"listingDate":1626753600000,"exchange":"NASDAQ","adjPreClose":1.57,"preHourTrading":{"tag":"盘前","latestPrice":1.85,"preClose":1.57,"latestTime":"09:25 EST","volume":7,"amount":11.3300005,"timestamp":1766413558267},"postHourTrading":{"tag":"盘后","latestPrice":1.56,"preClose":1.56,"latestTime":"18:57 EST","volume":59,"amount":94.73,"timestamp":1766447873588},"volumeRatio":0.622004},"requestUrl":"/m/hq/s/HCWB","defaultTab":"news","newsList":[{"id":"2585690163","title":"HCW Biologics Secures $4M Through Warrant Exercise","url":"https://stock-news.laohu8.com/highlight/detail?id=2585690163","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585690163?lang=en_us&edition=fundamental","pubTime":"2025-11-21 06:06","pubTimestamp":1763676409,"startTime":"0","endTime":"0","summary":"The latest update is out from HCW Biologics ( ($HCWB) ). On November 19, 2025, HCW Biologics Inc. entered into an inducement agreement with an inst...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/hcw-biologics-secures-4m-through-warrant-exercise?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/hcw-biologics-secures-4m-through-warrant-exercise?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","HCWB","BK4539"],"gpt_icon":0},{"id":"2585150474","title":"HCW Biologics Raises $4 Million Through Private Placement of Unregistered Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2585150474","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585150474?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:31","pubTimestamp":1763674261,"startTime":"0","endTime":"0","summary":"HCW Biologics Inc. has announced it has entered into a warrant inducement agreement with an investor for the immediate exercise of certain outstanding warrants, resulting in gross proceeds of approximately $4.0 million. As part of the agreement, the exercise price of the existing warrants was amended to $2.66 per share, with the investor exercising warrants to purchase a total of 1,510,205 shares of common stock. In consideration for the immediate exercise, HCW Biologics will also issue unregistered warrants to purchase an additional 3,020,410 shares at an exercise price of $2.41 per share. These new warrants are being offered in a private placement and are not registered under the Securities Act of 1933. The company plans to file a registration statement for the resale of shares issuable upon exercise of the new warrants. Maxim Group LLC is serving as the exclusive financial advisor for the transaction. Closing is expected on or about November 20, 2025, subject to customary conditions","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL1KJknw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","HCWB"],"gpt_icon":0},{"id":"2584944977","title":"BRIEF-Hcw Biologics Announces Warrant Inducement Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2584944977","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584944977?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:48","pubTimestamp":1763560085,"startTime":"0","endTime":"0","summary":"BRIEF-Hcw Biologics Announces Warrant Inducement AgreementNov 19 (Reuters) - HCW Biologics Inc HCWB.O:HCW BIOLOGICS INC - ANNOUNCES WARRANT INDUCEMENT AGREEMENTHCW BIOLOGICS INC - GROSS PROCEEDS FROM ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nFWN3WV10T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","HCWB","BK4139"],"gpt_icon":0},{"id":"2584745941","title":"HCW Biologics Inc - Announces Warrant Inducement Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2584745941","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584745941?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:31","pubTimestamp":1763559063,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nFWN3WV10T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HCWB","BK4539","BK4139"],"gpt_icon":0},{"id":"2584378944","title":"HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2584378944","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584378944?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:30","pubTimestamp":1763559000,"startTime":"0","endTime":"0","summary":"MIRAMAR, Fla., Nov.  19, 2025  (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and develop","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/19/3190945/0/en/HCW-Biologics-Enters-into-4-0-Million-Warrant-Inducement-Priced-At-the-Market-Under-Nasdaq-Rules.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSYW.SI","NQmain","SQQQ","MNQmain","BK4539","TQQQ","BK4139","USAW.SI","USJW.SI","PSQ","QLD","QID","NVIW.SI","HCWB",".IXIC"],"gpt_icon":1},{"id":"2584576932","title":"HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2584576932","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584576932?lang=en_us&edition=fundamental","pubTime":"2025-11-18 20:25","pubTimestamp":1763468700,"startTime":"0","endTime":"0","summary":"First Patient Dosed at The Ohio State University Wexner Medical Center in this Multi-Center Trial Active component of HCW9302 is interleukin-2 -- cytokine that maintains proper numbers and functions o","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/18/3189881/0/en/HCW-Biologics-Announces-Initiation-of-First-In-Human-Clinical-Trial-to-Evaluate-HCW9302-in-an-Autoimmune-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HCWB","BK4539"],"gpt_icon":0},{"id":"2583829356","title":"HCW Biologics Q3 EPS $(2.02) Misses $1.58 Estimate, Sales $15.606M Beat $7.000M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583829356","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583829356?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:47","pubTimestamp":1763156840,"startTime":"0","endTime":"0","summary":"HCW Biologics (NASDAQ:HCWB) reported quarterly losses of $(2.02) per share which missed the analyst consensus estimate of $1.58 by 227.85 percent. This is a 49.5 percent increase over losses of $(4.00) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48882005/hcw-biologics-q3-eps-2-02-misses-1-58-estimate-sales-15-606m-beat-7-000m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"HCW Biologics Q3 EPS $(2.02) Misses $1.58 Estimate, Sales $15.606M Beat $7.000M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCWB"],"gpt_icon":0},{"id":"2582873134","title":"HCW Biologics Unveils Promising Preclinical Data for Next-Gen Immune Checkpoint Inhibitor HCW11-040","url":"https://stock-news.laohu8.com/highlight/detail?id=2582873134","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582873134?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:04","pubTimestamp":1762776296,"startTime":"0","endTime":"0","summary":"HCW Biologics Inc. has announced updated preclinical data for its lead product candidate, HCW11-040, a second-generation, tetra-valent pembrolizumab-based immune checkpoint inhibitor. The data were presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer , held from November 5 to 9, 2025. HCW11-040 is a multi-functional fusion protein constructed using the company's TRBC platform and includes IL-15 and IL-7 domains as well as a TGF-β trap. Preclinical results demonstrated that HCW11-040 has PD-1/PD-L1 blocking activity comparable to pembrolizumab and showed enhanced expansion and activation of memory T cells, as well as improved anti-tumor activity against pancreatic cancer and leukemia cells in organoid models, without inducing excessive inflammatory responses. The company indicated plans to advance further IND-enabling studies for HCW11-040.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT striv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL79Kr1s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HCWB","BK4539"],"gpt_icon":0},{"id":"2581007432","title":"HCW Biologics announces data presented for TCE Program based on TRBC platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2581007432","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581007432?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:12","pubTimestamp":1762517549,"startTime":"0","endTime":"0","summary":"HCW Biologics (HCWB) announced the data presented for their tetra-valent, second-generation T-Cell Engager, TCE, Program based on their novel TRBC ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/hcw-biologics-announces-data-presented-for-tce-program-based-on-trbc-platform-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/hcw-biologics-announces-data-presented-for-tce-program-based-on-trbc-platform-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCWB","BK4139","BK4539"],"gpt_icon":0},{"id":"2581007360","title":"HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2581007360","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581007360?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:00","pubTimestamp":1762516800,"startTime":"0","endTime":"0","summary":"Tetra-valent T-cell engager designed to address shortfalls of bi-specific T-cell engagers (BiTE) related to manufacturability, safety profile, and ability to treat a wide spectrum of solid tumorsMIRAM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/07/3183532/0/en/HCW-Biologics-Presents-Preclinical-Data-for-TRBC-Based-T-Cell-Engager-Program-at-the-Society-for-Immunotherapy-of-Cancer-s-SITC-40th-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1103","IE00B12V2V27.USD","01308","IE00BYQNZ168.SGD","BK4139","BK1541","IE00BYTNYN87.SGD","HCWB","SG9999011746.SGD","BK4539","IE0003795394.USD","PDX","IE0003851619.USD"],"gpt_icon":0},{"id":"2577089367","title":"HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=2577089367","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577089367?lang=en_us&edition=fundamental","pubTime":"2025-10-22 21:00","pubTimestamp":1761138000,"startTime":"0","endTime":"0","summary":"Watch the \"What This Means\" video here Featuring the Company’s pembrolizumab-based immune checkpoint inhibitor  MIRAMAR, Fla., Oct.  22, 2025  (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/22/3171189/0/en/HCW-Biologics-Inc-NASDAQ-HCWB-Participates-in-Virtual-Investor-What-This-Means-Segment.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNQmain","SQQQ","NQmain","HCWB","TSYW.SI","PSQ","QLD","BK4539",".IXIC","BK4139","USAW.SI","QID","USJW.SI","NVIW.SI","TQQQ"],"gpt_icon":1},{"id":"2575747928","title":"HCW Biologics’ Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2575747928","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575747928?lang=en_us&edition=fundamental","pubTime":"2025-10-16 21:15","pubTimestamp":1760620500,"startTime":"0","endTime":"0","summary":"Company poster presentations will debut research data of three lead drug candidates constructed with Company’s novel TRBC platform technologyMIRAMAR, Fla., Oct.  16, 2025  (GLOBE NEWSWIRE) -- HCW Biol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/16/3167995/0/en/HCW-Biologics-Scientists-to-Present-Three-Posters-During-the-40th-Annual-Meeting-of-the-Society-for-Immunotherapy-of-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCWB","BK4139","BK4539","MMAT"],"gpt_icon":0},{"id":"2575774181","title":"HCW Biologics Granted Nasdaq Extension to Regain Compliance with Listing Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2575774181","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575774181?lang=en_us&edition=fundamental","pubTime":"2025-10-16 21:01","pubTimestamp":1760619665,"startTime":"0","endTime":"0","summary":"HCW Biologics Inc. has announced that it received notice from the Nasdaq Stock Market regarding non-compliance with the equity requirement for continued listing on the Nasdaq Capital Market. The company was found non-compliant as of June 30, 2025, and subsequently requested a hearing before the Nasdaq Hearings Panel. Following the hearing, the Panel granted HCW Biologics an extension to regain compliance with all listing rules. The company must meet the equity rule by December 31, 2025, and comply with all other listing requirements by February 16, 2026, which is the maximum extension permitted by the Panel. Failure to comply by these deadlines could result in delisting from the exchange.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nNDL6yCspN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","HCWB"],"gpt_icon":0},{"id":"2571328882","title":"HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2571328882","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571328882?lang=en_us&edition=fundamental","pubTime":"2025-09-30 20:45","pubTimestamp":1759236300,"startTime":"0","endTime":"0","summary":"Watch the \"What This Means\" video here Featuring Company’s second-generation T-Cell Engager programand advantages over first-generation Company’s T-Cell Engager program has made improvements in manufa","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/30/3158633/0/en/HCW-Biologics-Inc-NASDAQ-HCWB-Participates-in-Virtual-Investor-What-This-Means-Segment-About-its-Proprietary-T-Cell-Engager-Program.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QLD","HCWB","USJW.SI","NQmain","BK4139","PSQ","TSYW.SI","NVIW.SI","USAW.SI","MNQmain","SQQQ","QID",".IXIC","TQQQ","BK4539"],"gpt_icon":1},{"id":"2568470255","title":"Press Release: HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2568470255","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568470255?lang=en_us&edition=fundamental","pubTime":"2025-09-18 21:15","pubTimestamp":1758201300,"startTime":"0","endTime":"0","summary":"Wugen closed a $115 million equity financing led by. HCW Biologics Inc.  is a clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases. The Company's immunotherapeutics represent a new class of drugs that it believes have the potential to fundamentally change the treatment of cancer and many other diseases and conditions that are promoted by chronic inflammation -- and in doing so, improve patients' quality of life and potentially extend longevity. Chronic inflammation, including inflammaging, is believed to be a significant contributing factor to senescence-associated diseases and conditions that diminish healthspan, including many types of cancer, autoimmune diseases, and neurodegenerative diseases, as well as many indications that impact quality-of-life that are not life-threatening. The Company's lead product candidate, HCW9302, was developed using th","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","BK4604","BK4215","03160","TM","HCWB","BK4539","BK4588","BK4555","EQR","BK4585","BK4139"],"gpt_icon":0},{"id":"2568179844","title":"HCW Biologics’ Innovative Lead Candidate HCW11-040 Boosts Cancer Therapy Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2568179844","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568179844?lang=en_us&edition=fundamental","pubTime":"2025-09-18 05:15","pubTimestamp":1758143709,"startTime":"0","endTime":"0","summary":"Analyst Michael Okunewitch of Maxim Group maintained a Buy rating on HCW Biologics, retaining the price target of $35.00. Michael Okunewitch has gi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/hcw-biologics-innovative-lead-candidate-hcw11-040-boosts-cancer-therapy-potential-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/hcw-biologics-innovative-lead-candidate-hcw11-040-boosts-cancer-therapy-potential-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","HCWB","BK4139"],"gpt_icon":0},{"id":"2567024851","title":"HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2567024851","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567024851?lang=en_us&edition=fundamental","pubTime":"2025-09-16 20:00","pubTimestamp":1758024000,"startTime":"0","endTime":"0","summary":"Lead product candidate will be advanced to late IND-enabling studiesto prepare for clinical trials for evaluation in the treatment of solid tumors Discovery of unique combination of cytokines in multi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/16/3150763/0/en/HCW-Biologics-Designates-One-of-Its-Proprietary-TRBC-Pembrolizumab-Based-Immune-Checkpoint-Inhibitors-as-its-Franchise-Immunotherapeutic-for-Internal-Clinical-Development.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1917777945.USD","LU0265550359.USD","SG9999002224.SGD","IE00BJT1NW94.SGD","LU1023059063.AUD","LU1093756325.SGD","LU1934455194.USD","SG9999001176.USD","LU1066051811.HKD","LU0203347892.USD","IE00BBT3K403.USD","LU2361045086.USD","LU1989772840.SGD","SG9999014567.USD","LU0265550946.USD","MRK","LU0208291251.USD","HCWB","LU0965509101.SGD","SG9999014542.SGD","LU1061106388.HKD","LU0211331839.USD","LU0266013472.USD","LU0289739699.SGD","IE0009355771.USD","BK4516","BK4533","LU0320765646.SGD","SG9999015341.SGD","BK4559","LU1983299246.USD","LU1929549753.HKD","LU1989772923.USD","BK4139","IE00B4R5TH58.HKD","LU2089984988.USD","LU2361044949.HKD","LU1037948897.HKD","SG9999015358.SGD","LU1066051498.USD","LU0965508806.USD","LU1093756168.USD","LU1571399168.USD","SG9999002232.USD","LU0234572021.USD","LU1162221912.USD","IE00BLSP4239.USD","LU0098860793.USD","LU0965509283.SGD","LU1699723380.USD"],"gpt_icon":0},{"id":"2566979687","title":"Consumer Sentiment, Oil Inventory Reports Set for Release as US Futures Little Changed in Friday's Premarket Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2566979687","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566979687?lang=en_us&edition=fundamental","pubTime":"2025-09-12 20:03","pubTimestamp":1757678629,"startTime":"0","endTime":"0","summary":"US stock futures were little changed in Friday's premarket session ahead of consumer sentiment and oil inventory figures coming out later in the morning.The Dow Jones Industrial Average futures were o","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4200","NXTT","BK4134","HCWB","VSTD","RENT","GCTK","XTIA","BK4023","BK4082","RENT.AU","BK4539","BK4209","BK4122"],"gpt_icon":0},{"id":"2566976115","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2566976115","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566976115?lang=en_us&edition=fundamental","pubTime":"2025-09-12 19:42","pubTimestamp":1757677378,"startTime":"0","endTime":"0","summary":"GlucoTrack  shares were up nearly 161% in recent premarket activity Friday, a day after the company said that Sixth Borough Capital Fund committed to acquire up to $20 million of the company's common shares.HCW Biologics  stock was 79% higher, following a 0.9% drop in the previous session.IBEX  shares were up 28% after the company overnight reported higher fiscal Q4 adjusted earnings and revenue from a year earlier.Super Micro Computer  stock was 5.5% higher after the company said overnight it started volume deliveries of its Nvidia  Blackwell Ultra solutions, such as HGX B300 systems and GB300 NVL72 racks, to clients worldwide.Adobe  shares were up 2.9%, a day after the company logged stronger-than-expected fiscal Q3 results, driven by revenue growth in digital media and experience.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1852331112.SGD","NVD","3NVD.UK","SNVD.UK","LU1839511570.USD","2NVD.UK","GCTK","LU0511384066.AUD","LU1069344957.HKD","BK4106","IBEX","BK4579","LU1064131342.USD","LU0316494557.USD","LU1699723380.USD","BK4588","LU0528227936.USD","LU2125909593.SGD","LU2265009873.SGD","NVDY","NVD3.UK","HK0000320223.HKD","NVDS.UK","LU1923622291.USD","LU2089284900.SGD","LU2272731782.SGD","NVIW.SI","LU2210149790.SGD","LU1261432733.SGD","NVDX","LU2264538146.SGD","LU0187121727.USD","NVDU","SMCI","IE00B1BXHZ80.USD","HCWB","LU0708995401.HKD","IE00B19Z8X17.USD","IE00BK4W5M84.HKD","NVD2.UK","LU0276348264.USD","LU1791710400.SGD","NVDS","LU0265550359.USD","LU1861220033.SGD","IE00BYQQ9H92.USD","NVDD"],"gpt_icon":1},{"id":"2566992893","title":"Why Is HCW Biologics Stock Surging 102% Overnight?","url":"https://stock-news.laohu8.com/highlight/detail?id=2566992893","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566992893?lang=en_us&edition=fundamental","pubTime":"2025-09-12 13:27","pubTimestamp":1757654820,"startTime":"0","endTime":"0","summary":"HCW Biologics' stock jumped 102.72% to $6.73 after the company revealed the successful development of second-generation T-cell engagers for solid tumors.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/09/12/Financial-Chart-And-Investment-Graph-Ana.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/09/12/Financial-Chart-And-Investment-Graph-Ana.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/markets/equities/25/09/47636546/why-is-hcw-biologics-stock-surging-102-overnight","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/09/47636546/why-is-hcw-biologics-stock-surging-102-overnight","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4139","HCWB","BK4539"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hcwbiologics.com","stockEarnings":[{"period":"1week","weight":-0.164},{"period":"1month","weight":-0.2811},{"period":"3month","weight":-0.6148},{"period":"6month","weight":-0.6494},{"period":"1year","weight":-0.9131},{"period":"ytd","weight":-0.9126}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":0.0391},{"period":"3month","weight":0.0326},{"period":"6month","weight":0.128},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1685}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. The company was incorporated in 2018 and is headquartered in Miramar, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.125505},{"month":2,"riseRate":0.75,"avgChangeRate":0.149026},{"month":3,"riseRate":0.5,"avgChangeRate":-0.010659},{"month":4,"riseRate":0.25,"avgChangeRate":-0.1522},{"month":5,"riseRate":0.25,"avgChangeRate":-0.089644},{"month":6,"riseRate":0.5,"avgChangeRate":-0.08481},{"month":7,"riseRate":0.5,"avgChangeRate":0.007222},{"month":8,"riseRate":0.4,"avgChangeRate":-0.025444},{"month":9,"riseRate":0.4,"avgChangeRate":-0.08752},{"month":10,"riseRate":0.4,"avgChangeRate":0.021722},{"month":11,"riseRate":0.2,"avgChangeRate":-0.225966},{"month":12,"riseRate":0.2,"avgChangeRate":-0.093852}],"exchange":"NASDAQ","name":"HCW Biologics Inc.","nameEN":"HCW Biologics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"HCW Biologics Inc.(HCWB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest HCW Biologics Inc.(HCWB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"HCW Biologics Inc.,HCWB,HCW Biologics Inc.股票,HCW Biologics Inc.股票老虎,HCW Biologics Inc.股票老虎国际,HCW Biologics Inc.行情,HCW Biologics Inc.股票行情,HCW Biologics Inc.股价,HCW Biologics Inc.股市,HCW Biologics Inc.股票价格,HCW Biologics Inc.股票交易,HCW Biologics Inc.股票购买,HCW Biologics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"HCW Biologics Inc.(HCWB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest HCW Biologics Inc.(HCWB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction